BIOCRYST PHARMACEUTICALS, INC. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Jon P. Stonehouse (our principal executive officer (“PEO”) for the years reported); PEO total compensation $12.95M; PEO compensation actually paid $1.16M; Other NEO average total compensation $5.69M.
- 2024-12-31: PEO total compensation $8.32M; PEO compensation actually paid $10.98M; Other NEO average total compensation $3.37M.
- 2023-12-31: PEO total compensation $4.78M; PEO compensation actually paid -$3.69M; Other NEO average total compensation $1.96M.
- 2022-12-31: PEO total compensation $6.98M; PEO compensation actually paid $4.01M; Other NEO average total compensation $2.57M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Jon P. Stonehouse (our principal executive officer (“PEO”) for the years reported) | $12.95M | $1.16M | $5.69M | $3.09M | $104.70 | $200.89 | $263.86M | ORLADEYO sales $596.12M | 2026-04-23 |
| 2024-12-31 | $8.32M | $10.98M | $3.37M | $4.16M | $100.94 | $156.19 | -$88.88M | $434.09M | 2026-04-23 | |
| 2023-12-31 | $4.78M | -$3.69M | $1.96M | -$1.23M | $80.40 | $143.88 | -$226.54M | $323.81M | 2026-04-23 | |
| 2022-12-31 | $6.98M | $4.01M | $2.57M | $1.45M | $154.09 | $138.51 | -$247.12M | $249.69M | 2026-04-23 | |
| 2021-12-31 | $7.06M | $17.05M | $4.52M | $7.25M | $185.91 | $124.39 | -$184.06M | $121.86M | 2026-04-23 | |
| 2024-12-31 | Jon P. Stonehouse | $8.32M | $10.98M | $3.37M | $4.16M | $217.97 | $172.62 | -$88.88M | $434.09M | 2025-04-24 |
| 2023-12-31 | $4.78M | -$3.69M | $1.96M | -$1.23M | $173.62 | $159.01 | -$226.54M | $323.81M | 2025-04-24 | |
| 2022-12-31 | $6.98M | $4.01M | $2.57M | $1.45M | $332.75 | $153.08 | -$247.12M | $249.69M | 2025-04-24 | |
| 2021-12-31 | $7.06M | $17.05M | $4.52M | $7.25M | $401.45 | $137.47 | -$184.06M | $121.86M | 2025-04-24 | |
| 2020-12-31 | $6.03M | $10.85M | $2.35M | $3.63M | $215.94 | $110.52 | -$182.81M | $133.00K | 2025-04-24 | |
| 2023-12-31 | Jon P. Stonehouse | $4.78M | -$3.69M | $1.96M | -$1.23M | $173.62 | $159.01 | -$226.54M | ORLADEYO sales $323.81M | 2024-04-25 |
| 2022-12-31 | Jon P. Stonehouse | $6.98M | $4.01M | $2.57M | $1.45M | $332.75 | $153.08 | -$247.12M | $249.69M | 2024-04-25 |
| 2021-12-31 | Jon P. Stonehouse | $7.06M | $17.05M | $4.52M | $7.25M | $401.45 | $137.47 | -$184.06M | $121.86M | 2024-04-25 |
| 2020-12-31 | Jon P. Stonehouse | $6.03M | $10.85M | $2.35M | $3.63M | $215.94 | $110.52 | -$182.81M | $133.00K | 2024-04-25 |
| 2022-12-31 | Jon P. Stonehouse | $6.98M | $4.01M | $2.57M | $1.45M | $332.75 | $153.08 | -$247.12M | ORLADEYO Sales $249.69M | 2023-04-27 |
| 2021-12-31 | Jon P. Stonehouse | $7.06M | $17.05M | $4.52M | $7.25M | $401.45 | $137.47 | -$184.06M | $121.86M | 2023-04-27 |
| 2020-12-31 | Jon P. Stonehouse | $6.03M | $10.85M | $2.35M | $3.63M | $215.94 | $110.52 | -$182.81M | $133.00K | 2023-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |